Laty G. Thiam

Oct 23, 2024 | nature.com | Laty G. Thiam |Yicheng Guo |Saurabh Patel |Lawrence Shapiro |Simon Draper

AbstractVaccines to the Plasmodium falciparum reticulocyte binding-like protein homologue 5 (PfRH5) target the blood-stage of the parasite life cycle. PfRH5 has the potential to trigger the production of strain-transcendent antibodies and has proven its efficacy both in pre-clinical and early clinical studies. Vaccine-induced monoclonal antibodies (mAbs) to PfRH5 showed promising outcomes against cultured P. falciparum laboratory strains from distinct geographic areas.